Categories: News

Aidoc raises $110M to Address the Increasing Challenges Facing Health Systems by Using Artificial Intelligence

Funding for Aidoc’s AI Care Platform will bring new solutions for hospitals to address workload challenges and improve workflow processes, bringing cost savings and higher value care 

TEL AVIV, Israel, June 16, 2022 /PRNewswire/ — Aidoc, the leading provider of healthcare AI solutions, announced today a $110 million Series D round investment, bringing its total funding to $250 million. The round, co-led by global growth investors TCV and Alpha Intelligence Capital (AIC), with participation from AIC’s co-investor CDIB Capital, will power the continued expansion of the Aidoc AI Care Platform. The platform enables hospitals to tackle their most prominent challenges, especially in the post pandemic reality of physician and nursing shortages, rising supply costs, and an increasingly challenging economic environment.

“We are building the kind of breadth and depth in AI that is allowing hospitals to fundamentally change the way they do business and provide the solutions needed to successfully compete during these challenging times” says Elad Walach, CEO of Aidoc. “Aidoc is already the leading imaging AI platform, but with this new round of investment, our aim is to massively ramp up our AI Care Platform to cover both the various hospital medical service lines and the depth of integration into the clinical workflows, empowering hospitals to activate cross-specialty care teams and deliver the best quality of care in a scalable, efficient way to patients.”

Healthcare systems around the world currently face increasing challenges exacerbated by the pandemic. Currently, hospitals across the United States face growing labor shortages, with 30% choosing to retire and an additional 31% considering leaving the healthcare profession, according to Morning Consult – resulting in burnout and greater room for delayed or even missed care. The trend is expected to continue, and within five years, healthcare in the United States will be 3.2 million workers short. Moreover, these shortages have driven up operational costs, leading to hospitals in the U.S. suffering from red operating margins for the four consecutive months leading into 2022.

“These days it’s not business as usual for hospitals and health systems. Healthcare leaders face an increasingly tough economic environment and it’s going to require that we use technology like artificial intelligence to re-think ways to do business” says David Shulkin MD, former Secretary of the U.S. Department of Veterans Affairs.

Clinical research conducted on Aidoc’s AI solutions has shown its potential value in empowering physicians to manage larger patient volumes by reducing time to treatment, shortening length of stay in the ED and capturing more patients requiring advanced treatments. Now, Aidoc, is bringing its AI-driven clinical experience from medical imaging and multidisciplinary response teams to the entirety of the hospital enterprise—covering the key modalities, the various specialties and aiding physicians in managing the entire patient care continuum, all connected under the AI Care Platform.

The AI Care Platform, the first of its kind, already boasts 15 FDA-cleared clinical solutions, in addition to the Care Coordination application which operates as an intelligent layer on top of hospital IT systems, offering physicians a centralized solution to address care points, across the health system. The full platform empowers radiologists and other imaging professionals to triage potential time-critical cases and for the care team to conclude deep, actionable insights derived from imaging data, and electronic medical records. Through the Platform, physicians are empowered to spend more time engaging patients, being proactive and providing higher quality treatment, rather than being consumed by manual processes, being reactive to inbound requests and risking patients slipping through the cracks.

“Founded with a patient-focused and product-centric mentality, Aidoc has a bold vision to forge a new market category in healthcare and deep, established roots in medical imaging,” says Gopi Vaddi, General Partner at TCV. “We believe Aidoc’s platform will change the way hospitals operate and serve as the missing layer of intelligence needed to transform healthcare.”

“With this new round of financing, we are excited to strengthen our existing partnership with the team at Aidoc, whose products have a tangible impact on the treatment of patients at some of the world’s leading medical institutions,” says Uday Sandhu, Partner at Alpha Intelligence Capital. “AIC invests in companies with decisive algorithmic advantages and Aidoc, in our opinion, has the unique opportunity to continue using its AI expertise to improve patient outcomes and make physicians and hospitals more efficient.”

About Aidoc

Aidoc (aidoc.com) is the leading provider of artificial intelligence healthcare solutions that empower physicians to expedite patient treatment and enhance operational capabilities. Aidoc’s AI Care Platform—the first of its kind—offers health systems a singular platform solution that works with physicians to manage the entire patient lifecycle—from diagnostic aid, to consultation to suggested treatment paths to patient follow-up tools. In clinical studies, the Aidoc AI has proven to reduce turnaround time, shorten patient length of stay and improve patient outcomes.

About TCV

Founded in 1995, TCV was established with a clear vision: to capture opportunities in the technology market through a specialized and consistent focus on investing in high-growth companies. Since inception, the firm has built a track record of successfully backing businesses that have developed into dominant industry players across internet, software, fintech, and enterprise IT. TCV has invested over $16 billion to date and has helped guide CEOs through more than 145 IPOs and strategic acquisitions. TCV has invested in cutting edge technology companies including Airbnb, Believe, Brex, Dream Sports, FarEye, HireVue, Mollie, Nubank, Razorpay, Netflix, Nerdy, RELEX Solutions, Revolut, RMS, Sportradar, Spotify, and Zillow. TCV has successfully executed over 350 investments of varying structures, including mid-stage, late-stage and public company investments, and has offices in Menlo Park, New York, and London. For more information about TCV, including a complete list of TCV investments, visit www.tcv.com.

About AIC

Alpha Intelligence Capital (AIC) is a family of global venture capital funds investing in Artificial Intelligence/Machine Learning (AI/ML) technology-based companies. The team at AIC believes that AI is the Future. The funds focus on companies in the series A to series E stages that have deep expertise in the algorithmic sciences and the ability to develop breakthrough products to solve real business problems. AIC’s investment committee and advisory team include founders of leading Artificial Intelligence companies, Fortune 500 company executives, successful entrepreneurs, university professors, private equity and venture investors. AIC has personnel in San Francisco, Paris, Tel Aviv, Dubai, Singapore, and Hong Kong, and has investments in companies in the United States, Israel, the United Kingdom, France, Germany, Ireland, Slovakia, Hong Kong, and Singapore. For more information, visit www.aicapital.ai.

Contact:
Netanya Stein
WestRay Communications
netanya@westraycommunications.com 

View original content:https://www.prnewswire.com/news-releases/aidoc-raises-110m-to-address-the-increasing-challenges-facing-health-systems-by-using-artificial-intelligence-301569379.html

SOURCE Aidoc

Staff

Recent Posts

cbdMD Announces Company’s CEO Joins the Board of Directors

Charlotte, North Carolina--(Newsfile Corp. - December 23, 2024) - cbdMD, Inc. (NYSE American: YCBD) (NYSE…

6 hours ago

Interactive Strength Inc. (Nasdaq: TRNR) Issues Year-End Update, Looks Ahead to 2025

AUSTIN, TEXAS / ACCESSWIRE / December 23, 2024 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR" or…

7 hours ago

Quest Diagnostics Upholds Strong Governance and Ethics With Robust Oversight, ESG Integration, and Comprehensive Risk Management

Originally published in Quest Diagnostics' 2023 Corporate Responsibility ReportNORTHAMPTON, MA / ACCESSWIRE / December 23,…

7 hours ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Marlborough, Massachusetts--(Newsfile Corp. - December 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage…

8 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago

ILiAD Biotechnologies Announces the Passing of Chief Operating Officer Ken Solovay

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC (ILiAD), a clinical stage biotech company developing the world’s most…

10 hours ago